c-Kit
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| FB02271 | Sitravatinib | 1123837-84-2 | Sitravatinib is an inhibitor of receptor tyrosine kinase (RTK) involved in driving sarcoma cell growth, is developed for the treatment of cancer. |
| FB06885 | PLX647 | 873786-09-5 | PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respectively. |
| FB02622 | Pexidartinib | 1029044-16-3 | Pexidartinib is a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with IC50s of 20, 10, and 160 nM in vitro, respectively. |
| FB08551 | OSI-930 | 728033-96-3 | OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively and also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl. |
| FB17298 | JNJ-38158471 | 951151-97-6 | JNJ-38158471 is a well tolerated, orally available, highly selective VEGFR-2 inhibitor, with an IC50 of 40 nM. JNJ-38158471 also inhibits Ret and Kit with IC50s of 180 and 500 nM, respectively . |
| FB11088 | ISCK03 | 945526-43-2 | ISCK03 is a cell-permeable c-Kit inhibitor with IC50 < < 2.5 μM in cell-free kinase assays and blocks SCF-induced c-kit and Erk phosphorylation (1 μM causes > 90% inhibition) without any effect on HGF-induced Erk phosphorylation in 501mel melanoma cells, it's a phenyl-imidazolosulfonamide compound. |
| FB03848 | Imatinib Mesylate | 220127-57-1 | Imatinib Mesylate is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. |
| FB02852 | Imatinib | 152459-95-5 | Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. |
| FB02852 | Imatinib | 152459-95-5 | Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. |
| FB08539 | Dovitinib Lactate Hydrate | 915769-50-5 | Dovitinib lactate is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. |
| FB06436 | Dovitinib Lactate | 692737-80-7 | Dovitinib lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) with an IC50 of 5 nM. |
| FB07888 | Dovitinib | 405169-16-6 | Dovitinib is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM. |
| FB10159 | Dovitinib Dilactate | 852433-84-2 | Dovitinib dilactic acid is the dilactic acid of dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. |
| FB11733 | Ripretinib | 1442472-39-0 | DCC-2618 is a pan-KIT and PDGFRA inhibitor, and has antitumor activity. |
| FB02380 | DCC-2618 | 1225278-16-9 | DCC-2618 is a c-Kit and PDGFR inhibitor with IC50s of 6/30/13 nM for c-Kit/PDGFRα/PDGFRβ respectively. |
| FB11189 | c-KIT/PDGFRα Inhibitor C31 | 2101755-69-3 | c-KIT/PDGFRα inhibitor C31 is a potent, selective stem cell factor receptor/platelet derived growth factor receptor alpha (c-KIT/PDGFRα) dual inhibitor for the treatment of imatinib-resistant gastrointestinal stromal tumors GISTs). |
| FB12170 | BLU-285 | 1703793-34-3 | BLU-285 is a potent KIT receptor and PDGFRα dual inhibitor with IC50 of 0.27 and 0.24 nM for KIT (D816V) and PDGFRα (D842V) respectively, developed as a highly targeted therapy for SM. |
| FB03841 | Amuvatinib | 850879-09-3 | Amuvatinib is a potent and multi-targeted inhibitor that inhibits c-Kit, PDGFRα and Flt3 with IC50 of 10, 40 and 81 nM respectively. |